Armonair Digihaler (Fluticasone Propionate) Patent Expiration, LOE Window & CMS Spending

Armonair Digihaler (Fluticasone Propionate) by Teva Pharmaceuticals: FDA Orange Book LOE 2041-01-06, 12 AB generics, $377K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN208798 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-01-06
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$377K
2024 Medicare Part D Spend$336K
2024 Medicaid Spend$41K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.